Transaminase mutants and their applications

Abstract

The present invention provides a transaminase mutant and its application. The transaminase mutant includes (a) a protein having an amino acid sequence shown in SEQ ID NO: 1; or (b) a protein having amino acid mutations and having transaminase activity function at at least one of the following sites of the amino acid sequence in (a): V315, I91, V124, Y116, A286, C418, T87, S301, S27, V31, R34, M64, A74, R77, S101, T117, N151, L213, T285, T107 or L449; (c) a protein having more than 80% homology with the amino acid sequence defined in any one of (a) and (b) and having transaminase function. The invention can solve the problem of poor activity or tolerance of transaminase in the industrial production of catalyzing large sterically hindered chiral amine compounds in the prior art, and is applicable to the field of enzyme catalysis.

Description

Technical Field

[0001] The present invention relates to the field of enzyme catalysis, and in particular to a transaminase mutant and application thereof. Background Art

[0002] Chiral amines are the structural units of many important biologically active molecules and key intermediates for the synthesis of many chiral drugs. At present, there are three main methods for the synthesis of chiral amines, including chemical method, biological resolution method and biological asymmetric synthesis method. Among them, the chemical method has the disadvantages of long reaction routes and harsh conditions, the use of toxic transition metal catalysts in the synthesis, low product stereoselectivity and low yield; and the theoretical maximum yield of the biological resolution method is only 50%. Both methods have certain limitations in scale-up production.

[0003] The asymmetric synthesis of chiral amines catalyzed by transaminase has attracted more and more attention due to its advantages such as high selectivity, high conversion rate, mild reaction conditions and environmental friendliness, and has now become a widely used method for preparing chiral amines. However, most wild-type transaminases have a limited substrate range and are generally difficult to synthesize large sterically hindered chiral amine compounds (referring to the substituent on the side next to the carbonyl group of the catalytic substrate being larger than the methyl group). CN114875006 A discloses a transaminase mutant that can efficiently synthesize chiral amines, especially large sterically hindered chiral amines. However, these mutants have relatively poor stability when used in industrial applications and are difficult to adapt to extreme environments such as high temperature and high concentration of organic solvents in the scale-up process.

[0004] The tolerance of transaminases can be improved through enzyme evolution. Cao, J., et al. modified the thermal stability of the (R)-type transaminase from Aspergillus terreus, constructed 13 mutants through site-directed mutagenesis, and confirmed experimentally that 3 mutants (E133Q, D224K and E253A) contribute to the improvement of enzyme thermal stability, among which the stability of mutant D224K at 40°C was increased by 4.23 times (Front. Chem. 2021, 9: 664156.). In addition, Cai, B., et al. used the (R)-type transaminase from Aspergillus fumigatus Af293 to construct an enzymatic process for the efficient production of (R)-α-phenylethylamine. The activity of the mutants obtained through directed evolution increased by more than 3,000 times, and the tolerance to isopropylamine (2M) was greatly improved, and up to 168 g L was achieved in industrial test scale. –1 d –1 The yield of (R)-α-phenylethylamine was increased (Org. Process Res. Dev. 2022, 26, 7, 2004–2012).

[0005] Therefore, in order to further adapt to the industrial production requirements of synthesizing large sterically hindered chiral amines, we can improve the stability of transaminases under extreme conditions through enzyme evolution, so as to further promote the immobilization and continuous application of transaminases, improve production efficiency, reduce industrial production costs, and reduce industrial waste emissions. Summary of the invention

[0006] The main purpose of the present invention is to provide a transaminase mutant and its application, so as to solve the problem in the prior art that the transaminase has poor activity or tolerance in the industrial production of sterically hindered chiral amine compounds.

[0007] To achieve the above-mentioned object, according to the first aspect of the present invention, a transaminase mutant is provided, comprising (a) a protein having an amino acid sequence as shown in SEQ ID NO: 1; or (b) a protein having amino acid mutation at at least one of the following sites of the amino acid sequence in (a): V315, I91, V124, Y116, A286, C418, T87, S301, S27, V31, R34, M64, A74, R77, S101, T117, N151, L213, T285, T107 or L449 and having transaminase activity; and (c) a protein having more than 80% homology with the amino acid sequence defined in any one of (a) and (b) and having transaminase function.

[0008] Further, the amino acid mutations in (b) are each independently selected from the following: V315T or V315R or V315D or V315A or V315K or V315H; I91Q or I91M or I91N or I91G or I91F or I91D; V124C or V124S or V124Y or V124P or V124M or V124A or V124I; Y116F or Y116Y or Y116A or Y116R or Y116S or Y116G or Y 116H or Y116L; A286I or A286R or A286Q or A286F or A286D or A286M or A286I; C418L or C418W or C418R or C418D or C418F or C418A; T87A or T87Y or T87N or T87V or T87F or T87E; S301A or S301G or S301H or S301K or S301W or S301I or S301M or S301N; S27 A or S27V or S27N or S27M or S27E or S27R or S27; S101A or S101R or S101Y or S101H; R34H or R34K or R34N or R34T or R34F or R34M; T117V or T117M or T117L or T117T or T117R or T117S; T285M or T285Y or T285I or T285A or T285G; T107S or T107Q or T107A or T107G; wherein the letters before the numbers represent the original amino acids, and the letters after the numbers represent the mutant amino acids; preferably, in (c), the protein has more than 85%, preferably more than 90%, more preferably more than 95%, and further preferably more than 99% homology with the amino acid sequence defined in (a) or (b) and has transaminase function.

[0009] Further, the mutation of the transaminase mutant includes any of the following amino acid mutations: V315T; V315R; V315D; V315A; V315K; V315H; V315T+I91Q; V315T+I91M; V315T+I91N; V315T+I91G; V315T+I91F; V315T+I91D; V315T+V124C; V315T+V124S; V315T+V124Y; V315T+V124P; V315T+V124M; V315T+V124A; V315T+V124C+I91N; V315T+V124C+ I91Q; V315T+V124C+I91M; V315T+V124C+I91G; V315T+V124C+I91F; V315T+I91Q+V124S; V315T +I91Q+V124I; V315T+I91Q+V124P; V315T+I91Q+V124M; V315T+I91Q+V124A; V315T+I91Q+V12 4Y; V315T+I91Q+V124S+Y116F; V315T+I91Q+V124S+Y116Y; V315T+I91Q+V124S+Y116A; V315T +I91Q+V124S+Y116R; V315T+V124C+I91N+Y116F; V315T+V124C+I91N+Y116A; V315T+V124C+I 91N+Y116S; V315T+V124C+I91N+Y116G; V315T+V124C+I91N+Y116H; V315T+V124C+I91N+Y116L ; V315T+V124C+I91N+Y116F+A286I ; V315T+V124C+I91N+Y116F+A286R; V315T+V124C+I91N+Y116F+A286Q; V315T+V124C+I91N+Y116F+A286F; V315T+V124C+I91N+Y116F+A286D; V315T+V124C+I91N+Y116F+A286M; V315T+V124C+I91N+Y116F+A286I+C418L; V315T+V124C+I91N+Y116F+ A286I+C418W; V315T+V124C+I91N+Y116F+A286I+C418R; V315T+V124C +I91N+Y116F+A286I+C418D; V315T+V124C+I91N+Y116F+A286I+C418F;V315T+V124C+I91N+Y116F+A286I+C418A;V315T+V124C+I91N+Y116F+A286I+T87A;V315T+V124C+I91N+Y116F+A286I+T87Y;V315T+V124C+I91N+Y116F+A286I+T87N;V315T+V124C+I91N+Y116F+A286I+T87V;V315T+V124C+I91N+Y116F+A286I+T87F;

[0010] V315T+V124C+I91N+Y116F+A286I+T87E ;

[0011] V315T+V124C+I91N+Y116F+A286I+T87A+S301A ;

[0012] V315T+V124C+I91N+Y116F+A286I+T87A+S301G ;

[0013] V315T+V124C+I91N+Y116F+A286I+T87A+S301H ;

[0014] V315T+V124C+I91N+Y116F+A286I+T87A+S301K ;

[0015] V315T+V124C+I91N+Y116F+A286I+T87A+S301W ;

[0016] V315T+V124C+I91N+Y116F+A286I+T87A+S27A ;

[0017] V315T+V124C+I91N+Y116F+A286I+T87A+S27V ;

[0018] V315T+V124C+I91N+Y116F+A286I+T87A+S27N ;

[0019] V315T+V124C+I91N+Y116F+A286I+T87A+S27M ;

[0020] V315T+V124C+I91N+Y116F+A286I+T87A+S27E ;

[0021] V315T+V124C+I91N+Y116F+A286I+T87A+S27R ;

[0022] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A ;

[0023] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101R ;

[0024] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101Y ;

[0025] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101H ;

[0026] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34H ;

[0027] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34K ;

[0028] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34N ;

[0029] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34T ;

[0030] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34F ;

[0031] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+T117V ;

[0032] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+T117M ;

[0033] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301K ;

[0034] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301I ;

[0035] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301G ;

[0036] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301W ;

[0037] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H ;

[0038] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34T ;

[0039] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34N ;

[0040] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34F ;

[0041] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34M ;

[0042] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301M ;

[0043] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301K ;

[0044] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301I ;

[0045] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301N ;

[0046] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301A; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117L ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117T ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117R ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117S ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285Y ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285I ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285A ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285G ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107S ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107Q ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107A ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107G.

[0047] In order to achieve the above object, according to the second aspect of the present invention, a DNA molecule is provided, which encodes the above transaminase mutant.

[0048] In order to achieve the above object, according to the third aspect of the present invention, a recombinant plasmid is provided, wherein the recombinant plasmid is connected to the above DNA molecule.

[0049] In order to achieve the above object, according to a fourth aspect of the present invention, a host cell is provided, wherein the host cell is transformed with the above recombinant plasmid.

[0050] In order to achieve the above object, according to a fifth aspect of the present invention, a method for preparing a chiral amine compound is provided, the method comprising using the above transaminase mutant to perform a transamination reaction on a ketone substrate represented by formula I under the action of an amino donor to obtain a chiral amine compound,

[0051]

[0052] Ar1 is selected from the first substituted aryl, the first unsubstituted aryl, the substituted arylene or unsubstituted arylene, the substituted heteroarylene or unsubstituted heteroarylene; Ar2 is selected from the second substituted aryl, the second unsubstituted aryl, the substituted cycloalkyl or unsubstituted cycloalkyl, alkyl or alkylene; R is selected from H, alkyl, alkylene or alkylidene, the number of carbon atoms in the alkyl, alkylene or alkylidene is selected from 1 to 5, and the alkyl, alkylene or alkylidene includes substituted alkyl, alkylene or alkylidene or unsubstituted alkyl, alkylene or alkylidene; when R is selected from alkyl, alkylene or alkylidene, the alkyl, alkylene or alkylidene is connected to Ar1 and / or Ar2 to form a ring; the substituents in the first substituted aryl, substituted arylene, substituted heteroarylene, the second substituted aryl or substituted alkyl, alkylene or alkylidene are each independently selected from halogen, hydroxyl, amino, methyl, ethyl or -CH 2 CH 2 The heteroatom in the substituted heteroarylene group is selected from N, O or S.

[0053] Further, the substituents of the first substituted aryl group, the second substituted aryl group or the substituted arylene group are each independently selected from halogen.

[0054] Furthermore, the substituents are each independently located at any one or more positions of the ortho position, meta position or para position of the first substituted aryl group, the second substituted aryl group or the substituted arylene group.

[0055] Furthermore, the halogen is selected from F, Cl or Br.

[0056] Furthermore, Ar1 is selected from unsubstituted heteroarylene, Ar2 is selected from a second substituted aryl, the substituent of the second substituted aryl is selected from halogen, R is selected from a substituted alkylene, the number of C atoms of the substituted alkylene is selected from 1 to 5, the substituent is selected from hydroxyl, and the substituted alkylene is connected to Ar1 to form a ring.

[0057] Furthermore, Ar1 is selected from a first substituted aromatic group or a first unsubstituted aromatic group, the substituent of the first substituted aromatic group is selected from methyl or Cl, Ar2 is selected from an unsubstituted cycloalkyl group, an alkyl group or a second unsubstituted aromatic group, the number of C atoms of the unsubstituted cycloalkyl group is selected from 3 to 5, the alkyl group is selected from isopropyl or ethyl, R is selected from an alkyl group, and the alkyl group is selected from isopropyl, methyl or ethyl.

[0058] Further, Ar1 is selected from a first substituted aryl group, or a first unsubstituted aryl group, and the substituent of the first substituted aryl group is selected from methyl or -CH 2 CH 2 OH, Ar2 is selected from a second unsubstituted aromatic group or an alkyl group, the alkyl group is selected from a methyl group or an isopropyl group, R is selected from a substituted alkylene group, the number of C atoms of the substituted alkylene group is selected from 1 to 5, the substituent is selected from a hydroxyl group, and the substituted alkylene group is connected to Ar1 to form a ring.

[0059] Further, the ketone substrate is selected from

[0060]

[0061] By applying the technical scheme of the present invention, a transaminase mutant (SEQ ID NO: 1) derived from Chromobacterium violaceum was used as the parent, and protein engineering modifications such as saturation mutation and combination mutation were performed to obtain a transaminase mutant with greatly improved activity and tolerance in the reaction of catalyzing large sterically hindered chiral amines. DETAILED DESCRIPTION

[0062] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below in conjunction with the embodiments.

[0063] Terminology explanation:

[0064] Large sterically hindered chiral compound: in the present application, refers to a ketone compound in which the group next to the prochiral carbonyl group is larger than the methyl group, wherein the group larger than the methyl group may be ethyl, propyl, tert-butyl or tert-butyl phenyl, etc.

[0065] As mentioned in the background art, the chemical synthesis and biological resolution methods of chiral amines have many shortcomings. The use of biological asymmetric methods to synthesize chiral amines can be more efficient and its reaction conditions are milder. However, due to the limited substrate range of most wild-type transaminases, when synthesizing large sterically hindered chiral amine compounds, transaminases often have problems such as low activity and poor tolerance, and cannot be scaled up for production.

[0066] Therefore, in the present application, the inventors attempted to modify the transaminase by enzyme evolution, thereby improving the various properties of the transaminase under extreme conditions, so that the production efficiency can be improved in industrial production, and thus proposed a series of protection schemes of the present application.

[0067] In a first typical embodiment of the present application, a transaminase mutant is provided, comprising: (a) a protein having an amino acid sequence as shown in SEQ ID NO: 1; or (b) a protein having amino acid mutations at at least one of the following sites of the amino acid sequence in (a): V315, I91, V124, Y116, A286, C418, T87, S301, S27, V31, R34, M64, A74, R77, S101, T117, N151, L213, T285, T107 or L449 and having transaminase activity; (c) a protein having more than 80% homology with the amino acid sequence defined in any one of (a) and (b) and having transaminase function.

[0068] The amino acid sequence shown in the above SEQ ID NO: 1 is a transaminase mutant derived from Chromobacterium violaceum. By performing computer simulation analysis of homology modeling of the amino acid sequence and molecular docking with different large sterically hindered ketone compounds, 19 amino acid residues were found to include: S27, V31, R34, M64, A74, R77, T87, I91, S101, Y116, T117, V124, N151, L213, T285, A286, V315, C418 and L449. These amino acid sites may affect the catalytic activity and stability of the protein. By mutating the above amino acid sites, a protein with transaminase function or even enhanced transaminase function can be obtained. For the above-obtained protein, changes can be made at non-critical mutation sites and active sites, and a protein with more than 80% homology to the above amino acid sequence and transaminase function can be obtained.

[0069] The sequence of SEQ ID NO: 1 is as follows:

[0070] MQKQRTCSQWRELDAAHHLHPFTDTASLNQVGARVMTRGEGVYLWDCEGNKIIDGM

[0071] AGAWCVNMGYGRKDFAEAARRQMEELSFMHTADGITHPAVVELSSLLAEVTPAGFDRVFY

[0072] TNSGSESVDCMIRMVRRYWDVQGKPEKKTLIGRWNGYSGSTIGGASLSGFKEMHEQGDLPI

[0073] PGVAHIEQPWWYKHGKDMTPDEFGVVAARWLEEKILEIGADKVAAFVGEPIQGAGGAIVPP

[0074] ATYWPEIERICRKYDVLLVADEVICGFGRTGEWFGHQHFGFQPDLFTAAKGLSSGYQPIGAVS

[0075] VGKRVAEGLIAGGVFYHGHTTSGHPVCAAVAHANVAALRDEGIVQRVKDDIGPYMQKRWR

[0076] ETLSRFEHVDDVRGVGMLAAFTLVKNKAKRELFPDFGEIGSLCRDIFVRNNLIMDICGDHIV

[0077] AAPPLVMTRAEVDEMLAVAERCLEELEQSLKARGLA。

[0078] In a preferred embodiment, the amino acid mutations in (b) are each independently selected from the following: V315T or V315R or V315D or V315A or V315K or V315H; I91Q or I91M or I91N or I91G or I91F or I91D; V124C or V124S or V124Y or V124P or V124M or V124A or V124I; Y116F or Y116Y or Y116A or Y116R or Y116S or Y116 G or Y116H or Y116L; A286I or A286R or A286Q or A286F or A286D or A286M or A286I; C418L or C418W or C418R or C418D or C418F or C418A; T87A or T87Y or T87N or T87V or T87F or T87E; S301A or S301G or S301H or S301K or S301W or S301I or S301M or S301N; S27 A or S27V or S27N or S27M or S27E or S27R or S27; S101A or S101R or S101Y or S101H; R34H or R34K or R34N or R34T or R34F or R34M; T117V or T117M or T117L or T117T or T117R or T117S; T285M or T285Y or T285I or T285A or T285G; T107S or T107Q or T107A or T107G; wherein the letters before the numbers represent the original amino acids, and the letters after the numbers represent the mutant amino acids; preferably, in (c), the protein has more than 85%, preferably more than 90%, more preferably more than 95%, and further preferably more than 99% homology with the amino acid sequence defined in (a) or (b) and has transaminase function.

[0079] As used herein, amino acid residues are abbreviated as follows: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine ​​(Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y) and valine (Val; V).

[0080] Substitution and replacement rules. Generally speaking, amino acids with similar properties will have similar effects after replacement. For example, conservative amino acid replacements may occur in the above homologous proteins. "Conservative amino acid replacements" include but are not limited to:

[0081] Hydrophobic amino acids (Ala, Cys, Gly, Pro, Met, Val, Ile, Leu) are replaced by other hydrophobic amino acids;

[0082] The hydrophobic amino acids with bulky side chains (Phe, Tyr, Trp) are replaced by other hydrophobic amino acids with bulky side chains;

[0083] Amino acids with positively charged side chains (Arg, His, Lys) are replaced by other amino acids with positively charged side chains;

[0084] Amino acids with polar, uncharged side chains (Ser, Thr, Asn, Gln) are replaced by other amino acids with polar, uncharged side chains.

[0085] A person skilled in the art may also perform conservative substitutions on amino acids according to amino acid substitution rules well known to those skilled in the art, such as the "blosum62 scoring matrix" in the prior art.

[0086] In this application, the applicant continued to explore the above active sites and found that when the active sites mutated to different amino acids, the corresponding protein activities were also different, and specific mutations could enhance the transaminase activity. Through experimental exploration, it was found that the above specific mutations in the active sites could obtain proteins with enhanced activity. For the amino acid mutation sites of the transaminase protein, flexible selection and combination can be made in the above mutations.

[0087] In a preferred embodiment, the mutation of the transaminase mutant includes any of the following amino acid mutations:

[0088] V315T;V315R;V315D;V315A;V315K;V315H;V315T+I91Q;V315T+I91M;V315T+I91N;V315T+I91G;V315T+I91F;V315T+I91D;V315T+V124C;V315T+V124S;V315T+V124Y;V315T+V124P;V315T+V124M;V315T+V124A;V315T+V124C+I91N;V315T+V124C+I91Q;V315T+V124C+I91M;V315T+V124C+I91G;V315T+V124C+I91F;V315T+I91Q+V124S;V315T+I91Q+V124I;V315T+I91Q+V124P;V315T+I91Q+V124M;V315T+I91Q+V124A;V315T+I91Q+V124Y;V315T+I91Q+V124S+Y116F;V315T+I91Q+V124S+Y116Y;V315T+I91Q+V124S+Y116A;V315T+I91Q+V124S+Y116R;V315T+V124C+I91N+Y116F;V315T+V124C+I91N+Y116A;V315T+V124C+I91N+Y116S;V315T+V124C+I91N+Y116G;V315T+V124C+I91N+Y116H;V315T+V124C+I91N+Y116L;V315T+V124C+I91N+Y116F+A286I; V315T+V124C+I91N+Y116F+A286R;V315T+V124C+I91N+Y116F+A286Q; V315T+V124C+I91N+Y116F+A286F;V315T+V124C+I91N+Y116F+A286D; V315T+V124C+I91N+Y116F+A286M;V315T+V124C+I91N+Y116F+A286I+C418L;V315T+V124C+I91N+Y116F+A286I+C418W;V315T+V124C+I91N+Y116F+A286I+C418R;V315T+V124C+I91N+Y116F+A286I+C418D;V315T+V124C+I91N+Y116F+A286I+C418F;V315T+V124C+I91N+Y116F+A286I+C418A;V315T+V124C+I91N+Y116F+A286I+T87A;V315T+V124C+I91N+Y116F+A286I+T87Y;V315T+V124C+I91N+Y116F+A286I+T87N;V315T+V124C+I91N+Y116F+A286I+T87V;V315T+V124C+I91N+Y116F+A286I+T87F;V315T+V124C+I91N+Y116F+A286I+T87E;V315T+V124C+I91N+Y116F+A286I+T87A+S301A ;V315T+V124C+I91N+Y116F+A286I+T87A+S301G ;V315T+V124C+I91N+Y116F+A286I+T87A+S301H ;V315T+V124C+I91N+Y116F+A286I+T87A+S301K ;V315T+V124C+I91N+Y116F+A286I+T87A+S301W ;

[0089] V315T+V124C+I91N+Y116F+A286I+T87A+S27A ;

[0090] V315T+V124C+I91N+Y116F+A286I+T87A+S27V ;

[0091] V315T+V124C+I91N+Y116F+A286I+T87A+S27N ;

[0092] V315T+V124C+I91N+Y116F+A286I+T87A+S27M ;

[0093] V315T+V124C+I91N+Y116F+A286I+T87A+S27E ;

[0094] V315T+V124C+I91N+Y116F+A286I+T87A+S27R ;

[0095] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A ;

[0096] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101R ;

[0097] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101Y ;

[0098] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101H ;

[0099] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34H ;

[0100] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34K ;

[0101] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34N ;

[0102] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34T ;

[0103] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34F ;

[0104] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+T117V ;

[0105] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+T117M ;

[0106] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301K ;

[0107] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301I ;

[0108] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301G ;

[0109] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301W ;

[0110] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H ;

[0111] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34T ;

[0112] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34N ;

[0113] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34F ;

[0114] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34M ;

[0115] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301M ;

[0116] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301K ;

[0117] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301I ;

[0118] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301N ;

[0119] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301A ;

[0120] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V ;

[0121] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117L ;

[0122] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117T ;

[0123] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117R;

[0124] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117S;

[0125] V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285Y ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285I ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285A ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285G ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107S ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107Q ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107A ;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107G.

[0126] The above amino acid mutations were all experimentally investigated in the examples of the present application, and all had transaminase activity. Compared with the parent having the amino acid sequence shown in SEQ ID NO: 1, transaminase mutants with higher stability, high tolerance to extreme environments, high enzyme activity, and which can be used for industrial scale-up production can be obtained.

[0127] In a second typical embodiment of the present application, a DNA molecule is provided, which encodes the above-mentioned transaminase mutant.

[0128] In a third typical embodiment of the present application, a recombinant plasmid is provided, wherein the recombinant plasmid is connected to the above-mentioned DNA molecule.

[0129] The DNA can encode the transaminase mutant and can be connected to a recombinant plasmid to form a circular DNA. Both the DNA and the recombinant plasmid can be transcribed and translated under the action of RNA polymerase, ribosome, tRNA, etc. to obtain the transaminase mutant.

[0130] In a fourth typical embodiment of the present application, a host cell is provided, wherein the above-mentioned recombinant plasmid is transformed. The host cell can be a prokaryotic cell or a eukaryotic cell. Specifically, the prokaryotic cell can be Escherichia coli, and the eukaryotic cell can be yeast.

[0131] By using the above host cells, the recombinant plasmid can be replicated in the host cells, and the DNA molecules carried on the recombinant plasmid can also be transcribed and translated to obtain a large number of transaminase mutants. By using the existing technology, the host cells can be crushed for protein purification, crushed for crude enzyme catalysis or other methods to obtain transaminase mutants, and then catalyze amine compounds. The host cell is a non-plant-derived host cell.

[0132] In a fifth typical embodiment of the present application, a method for preparing a chiral amine compound is provided, the method comprising using the above-mentioned aminotransferase mutant to perform a transamination reaction on a ketone substrate shown in formula I under the action of an amino donor to prepare a chiral amine compound; Ar1 ​​is selected from a first substituted aryl, a first unsubstituted aryl, a substituted arylene or an unsubstituted arylene, a substituted heteroarylene or an unsubstituted heteroarylene; Ar2 is selected from a second substituted aryl, a second unsubstituted aryl, a substituted cycloalkyl or an unsubstituted cycloalkyl, an alkyl or an alkylene; R is selected from H, alkyl, alkylene or alkylidene, the number of carbon atoms in the alkyl, alkylene or alkylidene is selected from 1 to 5, and the alkyl, alkylene or alkylidene includes substituted alkyl, alkylene or alkylidene or unsubstituted alkyl, alkylene or alkylidene; when R is selected from alkyl, alkylene or alkylidene, the alkyl, alkylene or alkylidene is connected to Ar1 and / or Ar2 to form a ring; the substituents in the first substituted aryl, substituted arylene, substituted heteroarylene, the second substituted aryl or substituted alkyl, alkylene or alkylidene are each independently selected from halogen, hydroxyl, amino, methyl, ethyl or -CH 2 CH 2 The heteroatom in the substituted heteroarylene group is selected from N, O or S.

[0133]

[0134] By using the above preparation method, the above transaminase mutant is used to perform a transamination reaction on the ketone compound shown in formula I under the action of an amino donor to obtain a chiral amine compound. The above transaminase mutant can perform chiral catalysis on the above ketone compound to synthesize the required large sterically hindered chiral amine. The activity and tolerance of the transaminase are greatly improved, so that it can catalyze under industrial production conditions such as extreme environments, which can improve production efficiency and reduce industrial production costs.

[0135] In a preferred embodiment, the substituents of the first substituted aryl group, the second substituted aryl group or the substituted arylene group are each independently selected from halogen.

[0136] In a preferred embodiment, the substituents are independently located at any one or more positions of the ortho, meta or para position of the first substituted aryl group, the second substituted aryl group or the substituted arylene group.

[0137] In a preferred embodiment, the halogen is selected from F, Cl or Br.

[0138] In a preferred embodiment, Ar1 is selected from unsubstituted heteroarylene, Ar2 is selected from a second substituted aryl, the substituent of the second substituted aryl is selected from halogen, R is selected from a substituted alkylene, the number of C atoms of the substituted alkylene is selected from 1 to 5, the substituent is selected from hydroxyl, and the substituted alkylene is connected to Ar1 to form a ring.

[0139] In a preferred embodiment, Ar1 is selected from a first substituted aromatic group or a first unsubstituted aromatic group, the substituent of the first substituted aromatic group is selected from methyl or Cl, Ar2 is selected from an unsubstituted cycloalkyl group, an alkyl group or a second unsubstituted aromatic group, the number of C atoms of the unsubstituted cycloalkyl group is selected from 3 to 5, the alkyl group is selected from isopropyl or ethyl, R is selected from an alkyl group, and the alkyl group is selected from isopropyl, methyl or ethyl.

[0140] In a preferred embodiment, Ar1 is selected from a first substituted aryl group, or a first unsubstituted aryl group, and the substituent of the first substituted aryl group is selected from methyl or -CH 2 CH 2 OH, Ar2 is selected from a second unsubstituted aromatic group or an alkyl group, the alkyl group is selected from a methyl group or an isopropyl group, R is selected from a substituted alkylene group, the number of C atoms of the substituted alkylene group is selected from 1 to 5, the substituent is selected from a hydroxyl group, and the substituted alkylene group is connected to Ar1 to form a ring.

[0141] In a preferred embodiment, the ketone compound is selected from: (Substrate 1),

[0142] (Substrate 2), (Substrate 3), (Substrate 4),

[0143] (Substrate 5), (Substrate 6), (Substrate 7),

[0144] (Substrate 8), (Substrate 9), (Substrate 10),

[0145] (Substrate 11), (Substrate 12), (Substrate 13),

[0146] (Substrate 14), (Substrate 15), (Substrate 16)

[0147] (Substrate 17).

[0148] In the present application, the inventors conducted homology modeling on the selected mutants based on the resolved three-dimensional structure of the protein (PDB: 4BA5), conducted molecular docking on different large sterically hindered ketone compounds based on the model structure, and under the guidance of the above-mentioned strategy for improving protein stability, selected 19 residues that may affect the catalytic activity and stability of the protein for modification, including: S27, V31, R34, M64, A74, R77, T87, I91, S101, Y116, T117, V124, N151, L213, T285, A286, V315, C418 and L449. The protein modification methods include saturation mutation and combined mutation.

[0149] Saturation mutagenesis is a method of modifying the coding gene of the target protein to obtain mutants in which the amino acids at the target site are replaced by 19 other amino acids in a short period of time. This method is not only a powerful tool for protein-directed modification, but also an important means of studying the structure-function relationship of proteins. Saturation mutagenesis often produces more ideal evolutionary bodies than single-point mutations. These problems that cannot be solved by the site-directed mutagenesis method are precisely the unique features of the saturation mutagenesis method. The construction of saturation mutagenesis adopts the method of whole plasmid PCR, and then the PCR product is digested with DPNI enzyme to remove the template and transformed into Escherichia coli BL21 (DE3). The screening of mutants often requires high-throughput screening methods. Therefore, we developed the following method to screen mutant tolerance.

[0150] The following high-throughput screening method was developed to screen the mutant library:

[0151] 1. Mutant culture: Add 300 μL LB medium to each well of a 96-well plate, inoculate the single clone on the agar plate into a deep-well 96-well plate, and culture overnight at 37°C and 200 rpm; use Qpix to transfer the overnight cultured bacterial solution to another 96-well plate, add 800 μL LB medium to each well, and culture at 37°C and 200 rpm for 5 hours. When the OD600 of the bacterial solution in the 96-well plate reaches 0.6-0.9, use Qpix to add IPTG solution to the 96-well plate again to make the final concentration of IPTG in the well plate 0.1 mM, and induce overnight at 25°C and 200 rpm for about 16 hours; centrifuge at 4000 rpm for 5 minutes, discard the supernatant, and use whole cells for reaction.

[0152] 2. 96-well plate high-throughput screening system:

[0153] 8 μL PLP mother solution (1 mg / mL), 3.5 μL 6M isopropylamine hydrochloride (20 eq), 0.1M Tris-Cl 9.0 were added to 100 μL and mixed, and the mixed sample was dispensed into each well of a 96-well plate with bacterial sludge, and finally the substrate mother solution (0.3 mg substrate dissolved in different concentrations of methanol) was added, mixed, and reacted for 18 hours at 50°C constant temperature shaker 700 rpm. After that, 3 volumes of methanol were added to each well, centrifuged, and the supernatant was sent to UPLC for analysis.

[0154] Through the above-mentioned initial screening of mutants, mutants with improved traits are obtained. Then, the optimal mutant will be induced in a 2L shake flask (the best conditions for inducing expression: 25°C, 0.2mM IPTG overnight induction), and after centrifugation to obtain bacterial sludge, the crude enzyme solution is obtained by ultrasonic cell disruption, and finally a g-scale reaction is performed to confirm the optimal mutant trait. Saturation mutations at a single site often have insignificant improvement effects, so multiple rounds of iterative saturation mutations are generally required to obtain mutants with greatly improved traits.

[0155] On the basis of the mutants with improved activity obtained by saturation mutation, the beneficial amino acid sites obtained by screening can be combined to obtain mutants with better traits. The construction method of double-point mutations in combined mutations is the same as that of single-point mutations, and is constructed by whole-plasmid PCR. Multi-point mutations that mutate 2 or more sites at the same time are amplified by overlapping extension PCR to obtain mutant genes containing multiple point mutations. After restriction endonuclease digestion at both ends, they are connected to the expression vector, transformed into Escherichia coli cells, and coated in LB culture dishes containing 100 μg / mL ampicillin. Cultured overnight at 37°C to obtain combined mutants. After the above-mentioned combined mutants are correctly identified by sequencing, the 2L shake flask induction culture and reaction verification as described above are carried out.

[0156] After multiple rounds of evolution, a series of transaminase mutants were obtained, and it was found that these mutants had greatly improved activity and tolerance in the catalytic reaction of large sterically hindered chiral amines. These mutants have been proven to be well used in the industrial production of large sterically hindered chiral amines.

[0157] The present application is further described in detail below in conjunction with specific embodiments. These embodiments should not be construed as limiting the scope of protection claimed in the present application.

[0158] The following Examples 1-4 show changes in enzyme stability by conversion rates at different methanol concentrations and temperatures.

[0159] Example 1

[0160] Two rounds of saturation mutagenesis were performed on the basis of the parent SEQ ID NO: 1. The specific mutation sites are shown in the table below, and the catalytic activity of the mutants was tested under the following reaction conditions.

[0161] 1 mL reaction system includes 30 mg substrate 1 or substrate 2, 300 μL methanol, 1 mg PLP, 2 mg isopropylamine hydrochloride, 300 μL crude enzyme solution (prepared from 30 mg wet bacterial mud), pH 8.0 100 mM phosphate buffer, and reaction at 40°C for 18 h.

[0162] The test results are shown in the table below.

[0163] Table 1:

[0164]

[0165] Note: In the above table, + represents a conversion rate less than 10%, ++ represents a conversion rate greater than or equal to 10% and less than or equal to 20%. +++ represents a conversion rate greater than or equal to 20% and less than or equal to 30%, ++++ represents a conversion rate greater than or equal to 30% and less than or equal to 40%, +++++ represents a conversion rate greater than or equal to 40% and less than or equal to 50%, and ++++++ represents a conversion rate greater than or equal to 50% and less than or equal to 60%.

[0166] Example 2

[0167] Saturation mutation and combination mutation were continued on the basis of Example 1, and the activity of the mutations was screened according to the following reaction conditions:

[0168] 1 mL reaction system includes 30 mg substrate 1 or substrate 2, 400 μL methanol, 1 mg PLP, 2 mg isopropylamine hydrochloride, 300 μL crude enzyme solution (prepared from 30 mg wet bacterial mud), pH 8.0 100 mM phosphate buffer, and reaction at 40°C for 18 h.

[0169] The results are shown in the table below

[0170] Table 2:

[0171]

[0172] Note: In the above table, + represents a conversion rate less than 10%, ++ represents a conversion rate greater than or equal to 10% and less than or equal to 20%. +++ represents a conversion rate greater than or equal to 20% and less than or equal to 30%, ++++ represents a conversion rate greater than or equal to 30% and less than or equal to 40%, +++++ represents a conversion rate greater than or equal to 40% and less than or equal to 50%, and ++++++ represents a conversion rate greater than or equal to 50% and less than or equal to 60%.

[0173] Example 3

[0174] Based on Example 2, multiple rounds of saturation mutagenesis were performed, and the catalytic activity of the mutants was tested under the following reaction conditions:

[0175] 1 mL reaction system includes 30 mg substrate 1 or substrate 2, 500 μL methanol, 1 mg PLP, 2 mg isopropylamine hydrochloride, 150 μL crude enzyme solution (prepared from 15 mg wet bacterial mud), pH 8.0 100 mM phosphate buffer, and reaction at 40°C for 18 h.

[0176] The results are shown in the table below

[0177] Table 3:

[0178]

[0179] Note: In the above table, + represents a conversion rate less than 10%, ++ represents a conversion rate greater than or equal to 10% and less than or equal to 20%. +++ represents a conversion rate greater than or equal to 20% and less than or equal to 30%, ++++ represents a conversion rate greater than or equal to 30% and less than or equal to 40%, +++++ represents a conversion rate greater than or equal to 40% and less than or equal to 50%, and ++++++ represents a conversion rate greater than or equal to 50% and less than or equal to 60%.

[0180] Example 4

[0181] Based on Example 3, multiple rounds of saturation mutation were continued, and the catalytic activity of the mutants was tested according to the following reaction conditions:

[0182] 1 mL reaction system includes 50 mg substrate 1 or substrate 2, 600 μL methanol, 1 mg PLP, 2 mg isopropylamine hydrochloride, 100 μL crude enzyme solution (prepared from 10 mg wet bacterial mud), pH 8.0 100 mM phosphate buffer, and reaction at 50°C for 18 h.

[0183] Table 4:

[0184]

[0185]

[0186] Note: In the above table, + represents a conversion rate less than 10%, ++ represents a conversion rate greater than or equal to 10% and less than or equal to 20%. +++ represents a conversion rate greater than or equal to 20% and less than or equal to 30%, ++++ represents a conversion rate greater than or equal to 30% and less than or equal to 40%, +++++ represents a conversion rate greater than or equal to 40% and less than or equal to 50%, and ++++++ represents a conversion rate greater than or equal to 50% and less than or equal to 60%.

[0187] Example 5

[0188] Some mutants obtained in the above examples were selected to test the stability of the enzymes after treatment with high temperature and different organic solvents. The reactions were carried out under the following conditions:

[0189] 1 mL reaction system includes 50 mg substrate 1 or substrate 2, 1 mg PLP, 2 mg isopropylamine hydrochloride, 100 μL crude enzyme solution (prepared from 10 mg wet bacterial mud) treated at 70°C for 1 h or treated with methanol, ethanol, acetonitrile, ethyl acetate, dichloromethane, tert-methyl ether and n-heptane for 1 h, and the control is the same amount of enzyme solution without any treatment, pH 8.0 100 mM phosphate buffer, and reacted at 40°C for 18 h.

[0190] The results are shown in the table below

[0191] Table 5-1:

[0192]

[0193] Table 5-2:

[0194]

[0195] Table 6-1:

[0196]

[0197]

[0198] Table 6-2:

[0199]

[0200] Note: 1) In the above table, relative residual activity refers to the percentage of enzyme activity measured after the enzyme solution has been treated with extreme conditions such as high temperature and organic solvents, compared with the enzyme activity of the enzyme solution that has not been treated under extreme conditions under optimal conditions. Under the same treatment conditions, the higher the relative residual activity, the higher the stability of the enzyme under these conditions.

[0201] 2) In the control, * represents an activity that is 0.1-0.5 times higher than the parent; ** represents an activity that is 0.5-1.0 times higher than the parent; *** represents an activity that is 1.0-1.5 times higher than the parent; **** represents an activity that is 1.5-2 times higher than the parent.

[0202] 3) + represents the relative residual activity greater than or equal to 10% and less than 30%, ++ represents the relative residual activity greater than or equal to 30% and less than 50%, +++ represents the relative residual activity greater than or equal to 50% and less than 70%, and ++++ represents the relative residual activity greater than or equal to 70% and less than 90%.

[0203] From the above description of the embodiments, it can be seen that:

[0204] 1) The stability of the mutant obtained in this application at high temperature has been significantly improved;

[0205] 2) In terms of tolerance to organic solvents, in addition to the obvious improvement in tolerance to methanol, the tolerance to the above 6 commonly used organic solvents has been improved to varying degrees.

[0206] 3) In addition, the above control experiments show that enzyme evolution not only improves the stability of mutants, but also improves enzyme activity to varying degrees.

[0207] Example 6

[0208] Add 20 mL of 100 mmol / L phosphate buffer, 20 mL of 6 mol / L isopropylamine hydrochloride solution (2 vol), and 60 mL of methanol to a 250 mL four-necked bottle at room temperature and adjust the pH to 8.5-9.0. Then add 0.1 g of pyridoxal phosphate and 5 g of (Substrate 1), stir evenly, then add 2mL (0.5g wet bacterial mud / mL enzyme solution) of the transaminase mutant (V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M) based on SEQ ID NO: 1 and adjust the pH to 8.5-9.0. Heat to 50°C and stir to react. After the reaction is complete, adjust the system to pH=2-3 to denature the protein. After filtering, the filtrate is extracted with 50mL of methyl tert-butyl ether. Adjust the aqueous phase to pH=12 and extract twice with 50mL of methyl tert-butyl ether. Combine the organic phases, dry them with anhydrous magnesium sulfate, and concentrate them to no fraction under the conditions of T<40°C and P≤-0.06Mpa. Obtain the target product

[0209] HPLC detection showed purity>99%, de value>99%, yield 85%

[0210] Example 7

[0211] Add 20 mL of 100 mmol / L phosphate buffer, 20 mL of 6 mol / L isopropylamine hydrochloride solution (2 vol), and 60 mL of methanol to a 250 mL four-necked bottle at room temperature and adjust the pH to 8.5-9.0. Then add 0.1 g of pyridoxal phosphate and 5 g of (Substrate 2), stir evenly, then add 2mL (0.5g wet bacterial mud / mL enzyme solution) of the transaminase mutant (V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M) based on SEQ ID NO: 1 and adjust the pH to 8.5-9.0. Heat to 50°C and stir to react. After the reaction is complete, adjust the system to pH=2-3 to denature the protein. After filtering, the filtrate is extracted with 50mL of methyl tert-butyl ether. Adjust the aqueous phase to pH=12 and extract twice with 50mL of methyl tert-butyl ether. Combine the organic phases, dry them with anhydrous magnesium sulfate, and concentrate them to no fraction under the conditions of T<40°C and P≤-0.06Mpa. Obtain the target product

[0212] HPLC detection showed purity>99%, de value>99%, yield 84%

[0213] Example 8

[0214] Add 20 mL of 100 mmol / L phosphate buffer, 20 mL of 6 mol / L isopropylamine hydrochloride solution (2 vol), and 60 mL of methanol to a 250 mL four-necked bottle at room temperature and adjust the pH to 8.5-9.0. Then add 0.1 g of pyridoxal phosphate and 5 g of (Substrate 16), stir evenly, then add 2mL (0.5g wet bacterial mud / mL enzyme solution) of the transaminase mutant (V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M) based on SEQ ID NO: 1 and adjust the pH to 8.5-9.0. Heat to 50°C and stir to react. After the reaction is complete, adjust the system to pH=2-3 to denature the protein. After filtering, the filtrate is extracted with 50mL of methyl tert-butyl ether. Adjust the aqueous phase to pH=12 and extract twice with 50mL of methyl tert-butyl ether. Combine the organic phases, dry them with anhydrous magnesium sulfate, and concentrate them to no fraction under the conditions of T<40°C and P≤-0.06Mpa. Obtain the target product.

[0215] HPLC detection showed purity>99%, de value>99%, yield 75%

[0216] Example 9

[0217] Add 20 mL of 100 mmol / L phosphate buffer, 20 mL of 6 mol / L isopropylamine hydrochloride solution (2 vol), and 60 mL of methanol to a 250 mL four-necked bottle at room temperature and adjust the pH to 8.5-9.0. Then add 0.1 g of pyridoxal phosphate and 5 g of (Substrate 17), stir evenly, then add 2mL (0.5g wet bacterial mud / mL enzyme solution) of the transaminase mutant (V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M) based on SEQ ID NO: 1 and adjust the pH to 8.5-9.0. Heat to 50°C and stir to react. After the reaction is complete, adjust the system to pH=2-3 to denature the protein. After filtering, the filtrate is extracted with 50mL of methyl tert-butyl ether. Adjust the aqueous phase to pH=12 and extract twice with 50mL of methyl tert-butyl ether. Combine the organic phases, dry them with anhydrous magnesium sulfate, and concentrate them at T<40°C, P≤-0.06Mpa until there is no fraction. Obtain the target product

[0218] HPLC detection showed purity>99%, de value>99%, yield 80%

[0219] Example 10

[0220] Using the enzyme solution of the transaminase mutant (V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M) based on SEQ ID NO: 1, referring to the catalytic synthesis steps of Examples 6-9, the substrates 3-15 were catalyzed. The results are as follows:

[0221] Table 7:

[0222] Substrate Product Purity de value Yield 3 ＞99％ ＞99％ 81％ 4 ＞99％ ＞98％ 78％ 5 ＞99％ ＞99％ 82％ 6 ＞98％ ＞98％ 83％ 7 ＞98％ ＞99％ 82％ 8 ＞99％ ＞99％ 80％ 9 ＞98％ ＞99％ 81％ 10 ＞99％ ＞99％ 84％ 11 ＞99％ ＞99％ 82％ 12 ＞99％ ＞99％ 85％ 13 ＞98％ ＞99％ 87％ 14 ＞99％ ＞99％ 78％ 15 ＞99％ ＞99％ 83％

[0223] From the above description, it can be seen that the above embodiments of the present invention achieve the following technical effects:

[0224] 1) By evolving transaminases, mutants with improved activity and stability were obtained, which can be used to synthesize a variety of large sterically hindered chiral amines under high temperature and high organic solvent conditions without the need for heavy metal catalysts and toxic reagents, thus achieving green chemistry.

[0225] 2) The aminotransferase mutant has high biocatalytic activity, stable enzyme, high reaction substrate concentration, high product yield, greatly reduces three wastes, and saves production costs.

[0226] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A transaminase mutant, characterized in that: The transaminase mutant is a mutant having an amino acid mutation at the following positions of the amino acid sequence shown in SEQ ID NO: 1: V315T; V315T+I91Q; V315T+I91M; V315T+I91N; V315T+I91G; V315T+I91F; V315T+I91D; V315T+V124C; V315T+V124S; V315T+V124Y; V315T+V124P; V315T+V124M; V315T+V124A; V315T+V124C+I91N; V315T+V124C+I91Q; V315T+V124C+I91M; V315T+V124C+I91G; V315T+V124C+I91F; V315T+I91Q+V124S; V315T+I91Q+V124I; V315T+I91Q+V124P; V315T+I91Q+V124M; V315T+I91Q+V124A; V315T+I91Q+V124Y; V315T+I91Q+V124S+Y116F; V315T+I91Q+V124S+Y116Y; V315T+I91Q+V124S+Y116A; V315T+I91Q+V124S+Y116R; V315T+V124C+I91N+Y116F; V315T+V124C+I91N+Y116A; V315T+V124C+I91N+Y116S; V315T+V124C+I91N+Y116G; V315T+V124C+I91N+Y116H; V315T+V124C+I91N+Y116L; V315T+V124C+I91N+Y116F+A286I; V315T+V124C+I91N+Y116F+A286R; V315T+V124C+I91N+Y116F+A286Q; V315T+V124C+I91N+Y116F+A286F; V315T+V124C+I91N+Y116F+A286D; V315T+V124C+I91N+Y116F+A286M; V315T+V124C+I91N+Y116F+A286I+C418L;V315T+V124C+I91N+Y116F+A286I+C418W;V315T+V124C+I91N+Y116F+A286I+C418R;V315T+V124C+I91N+Y116F+A286I+C418D;V315T+V124C+I91N+Y116F+A286I+C418F;V315T+V124C+I91N+Y116F+A286I+C418A;V315T+V124C+I91N+Y116F+A286I+T87A;V315T+V124C+I91N+Y116F+A286I+T87Y;V315T+V124C+I91N+Y116F+A286I+T87N;V315T+V124C+I91N+Y116F+A286I+T87V;V315T+V124C+I91N+Y116F+A286I+T87F; V315T+V124C+I91N+Y116F+A286I+T87E; V315T+V124C+I91N+Y116F+A286I+T87A+S301A; V315T+V124C+I91N+Y116F+A286I+T87A+S301G; V315T+V124C+I91N+Y116F+A286I+T87A+S301H; V315T+V124C+I91N+Y116F+A286I+T87A+S301K; V315T+V124C+I91N+Y116F+A286I+T87A+S301W; V315T+V124C+I91N+Y116F+A286I+T87A+S27A; V315T+V124C+I91N+Y116F+A286I+T87A+S27V; V315T+V124C+I91N+Y116F+A286I+T87A+S27N; V315T+V124C+I91N+Y116F+A286I+T87A+S27M; V315T+V124C+I91N+Y116F+A286I+T87A+S27E; V315T+V124C+I91N+Y116F+A286I+T87A+S27R; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101R;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101Y;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101H;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34H;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34K;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34N;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34T;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+R34F;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+T117V;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+T117M;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301K;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301I;V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301G; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S301W; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34T; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34N; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34F; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34M; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301M; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301K; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301I; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301N; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+S301A; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117L; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117T; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117R; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117S; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285M; V315T+V 124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285Y; V315T+V124C+I91 N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T285I; V315T+V124C+I91N+Y116F+ A286I+T87A+S27A+S101A+R34H+T117V+T285A; V315T+V124C+I91N+Y116F+A286I+T8 7A+S27A+S101A+R34H+T117V+T285G; V315T+V124C+I91N+Y116F+A286I+T87A+S27A +S101A+R34H+T117V+T107S; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R 34H+T117V+T107Q; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117 V+T107A; V315T+V124C+I91N+Y116F+A286I+T87A+S27A+S101A+R34H+T117V+T107G; The letters before the numbers represent the original amino acids, and the letters after the numbers represent the mutated amino acids.

2. A DNA molecule, characterized in that The DNA molecule encodes the transaminase mutant according to claim 1.

3. A recombinant plasmid, characterized in that: The recombinant plasmid is connected to the DNA molecule according to claim 2.

4. A host cell, characterized in that The host cell is transformed with the recombinant plasmid according to claim 3.

5. A method for preparing a chiral amine compound, characterized in that: The preparation method comprises using the aminotransferase mutant according to claim 1 to perform a transamination reaction on a ketone substrate as shown below under the action of an amino donor to obtain a chiral amine compound. The ketone substrate is selected from:

Images